The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight ...
ZURICH, May 4 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday a new study showed that its Lucentis eye drug is safer than cancer drug Avastin for treating macular degeneration. Novartis said ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies ...
Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug ...
LONDON, June 11 (Reuters) - Roche's cancer drug Avastin is a cheap, effective treatment for preventing blindness and should be used routinely in countries that cannot afford the far more costly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results